Despite increase in referrals for mammography screening for high-risk women, actual screening numbers did not increase significantly.
Mammography screening numbers do not increase even after patients are told that they are at higher risk for breast cancer, according to a study published in the Journal of the American College of Radiology.
Researchers from Penn State Hershey Breast Center and Penn State Milton S. Hershey Medical Center in Hershey, PA, undertook a study to determine the effectiveness of introducing a standardized recommendation into mammography reports in order to recruit women who had a 20% or higher lifetime risk for breast cancer.
The study included patients who were screened in 2011 and 2013. The researchers reviewed the charts for annotations in the mammography reports addressing the patients' risk status and referral to a provider at the clinic.[[{"type":"media","view_mode":"media_crop","fid":"41000","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_7593375620072","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4259","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 85px; width: 100px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"©Sam72/Shutterstock.com","typeof":"foaf:Image"}}]]
The results showed that 173 patients in 2011 and 241 patients in 2013 fell into this high risk target group. In 2011, 40.5% of the women were given a recommendation to attend the risk assessment clinic, while 75.5% were recommended to in 2013. “Despite the overall increase in such recommendations by radiologists, only a modest increase occurred, from 11.4 percent to 14.3 percent, in patients that subsequently attended our risk assessment clinic,” the authors wrote.
The researchers concluded that even though physicians made more recommendations for screening to women at high risk of developing breast cancer, the actual number of screenings did not increase.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.